Shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) have been given a consensus rating of “Buy” by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.13.

APTO has been the topic of a number of analyst reports. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, August 14th. HC Wainwright raised Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $4.00 in a research report on Thursday, September 7th. Finally, ValuEngine downgraded Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

TRADEMARK VIOLATION WARNING: “Aptose Biosciences, Inc. (APTO) Receives Average Rating of “Buy” from Analysts” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/17/aptose-biosciences-inc-apto-receives-average-rating-of-buy-from-analysts.html.

Shares of Aptose Biosciences (NASDAQ:APTO) traded down 2.21% during mid-day trading on Thursday, hitting $1.33. The stock had a trading volume of 202,205 shares. The stock has a 50 day moving average of $1.49 and a 200-day moving average of $1.29. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $2.40. The stock’s market capitalization is $31.96 million.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.07. On average, equities research analysts predict that Aptose Biosciences will post ($1.06) earnings per share for the current year.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.